ERBB2 and mucinous adenocarcinoma: No randomized controlled trials have focused on the therapeutic benefit of HER2-directed therapy specifically in mucinous ovarian carcinoma, which genetically shares greater overlap with mucinous carcinomas of the pancreaticobiliary tract and colon than other epithelial ovarian carcinomas (Cheasley et al., 2019).